Worthington Enterprises (WOR) upgraded to buy as sales rise, new wins boost growth, and data center revenue expands. Click ...

After controlling shareholders failed to take Grindr private and controversies over data and the banning of the phrase “No ...

Burry is the kind of outspoken outcast who makes for a good character in a Michael Lewis book: a neurologist by training who ...

At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 ...

LinkedIn has launched its ‘Year in Review’ 2025, offering users a personalised recap of career milestones, network growth, ...

Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED ...

Discover groundbreaking advancements in urologic oncology, including new standards for prostate, kidney, and bladder cancer ...

European review finds strong prevention gains alongside workforce shortages and growing hospital drug spending across health systems.

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Spotify Wrapped season’s here once again. Here’s where to find your 2025 results. Spotify Wrapped is live. Here’s how you can see your results.

Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...